Latest Pharmaceutical Market News

Page 1 of 5
Xenitra has secured a three-year strategic cooperation agreement with JD Health carrying a non-binding A$100 million sales target across prescription medicines, OTC products, FSMP products and health products. The first order is expected in December, with sales targeted to begin in January 2027, but the agreement does not guarantee revenue or impose a penalty if the target is missed.
Victor Sage
Victor Sage
18 Nov 2026
Clever Culture Systems has secured $2.6 million to develop APAS Revolution, a smaller benchtop system aimed at pharmaceutical manufacturers not served by its existing platform. The funding combines a discounted share placement with new debt, while commercial launch is targeted for the first half of 2028.
Victor Sage
Victor Sage
3 Nov 2026
Recce Pharmaceuticals has cleared an active-comparator design for its pivotal Australian diabetic foot infection trial while an independent review of Indonesian Phase 3 data approaches. The biotech ended the quarter with A$1.04 million in cash, alongside expected tax rebates and unused financing facilities.
Victor Sage
Victor Sage
30 Oct 2026
Dimerix has secured Mexican composition of matter protection for its Phase 2-ready kidney drug DMX-652 until June 2041. The grant expands the asset’s patent estate ahead of planned clinical testing in acute kidney injury, although it brings no new clinical data or regulatory approval.
Victor Sage
Victor Sage
14 Sept 2026
Recce Pharmaceuticals narrowed its operating loss to AUD 15 million in FY26, progressing Phase 3 trials for its anti-infective RECCE 327 and securing key patents and commercial partnerships.
Ada Torres
Ada Torres
31 Aug 2026
Clever Culture Systems expanded its pharmaceutical customer base to eight in FY26, placing 11 APAS Independence instruments and completing its product offering with a contact plate module. Despite a $2.24 million net loss, the company expects meaningful sales growth in FY27 backed by a robust pipeline and disciplined financial management.
Victor Sage
Victor Sage
31 Aug 2026
Xenitra’s Hong Kong subsidiary Fukang has inked a three-year A$5 million procurement framework for specialised medical nutrition products, broadening its foothold beyond OTC medicines in China’s booming healthcare market.
Ada Torres
Ada Torres
18 Aug 2026
Neuren Pharmaceuticals saw a record Q2 with DAYBUE net sales hitting US$125 million, driven by strong uptake of the new STIX formulation. The company upgraded its 2026 royalty guidance following Acadia Pharmaceuticals’ sales boost and awaits key regulatory milestones in Europe and Japan.
Victor Sage
Victor Sage
5 Aug 2026
BLS Pharmaceuticals capped FY2026 with record quarterly revenue and operating cash flow, driven by international expansion and new supply agreements across regulated markets.
Victor Sage
Victor Sage
30 July 2026
Firebrick Pharma expanded its patent portfolio with grants in Canada and New Zealand while achieving 43% sales growth in FY26 despite steady operating expenses. The company is advancing Nasodine's commercial rollout across Southeast Asia and the US.
Ada Torres
Ada Torres
27 July 2026
CLINUVEL Pharmaceuticals is relocating its corporate headquarters to the United States and reducing its global workforce by up to 20%, realigning its operations to focus solely on the US pharmaceutical market and unlock greater capital access.
Ada Torres
Ada Torres
23 July 2026
Recce Pharmaceuticals has expanded its intellectual property footprint with a key patent granted in Vietnam for its RECCE® anti-infective drugs, reinforcing its presence in a critical Southeast Asian market grappling with high antibiotic resistance.
Victor Sage
Victor Sage
14 July 2026

Browse the archive

Full archive